Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
NCT01131234 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2014-12-23
Summary
This phase I clinical trial is studying the side effects and best dose of giving gamma-secretase inhibitor RO4929097 and cediranib maleate together in treating patients with advanced solid tumors. Gamma-secretase inhibitor RO4929097 and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate also may stop the growth of tumor cells by blocking blood flow to the tumor.
Conditions
- Adult Anaplastic Astrocytoma
- Adult Anaplastic Ependymoma
- Adult Anaplastic Oligodendroglioma
- Adult Brain Stem Glioma
- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma
- Adult Mixed Glioma
- Adult Solid Neoplasm
- Male Breast Carcinoma
- Recurrent Adult Brain Neoplasm
- Recurrent Breast Carcinoma
- Recurrent Colon Carcinoma
- Recurrent Melanoma
- Recurrent Non-Small Cell Lung Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Ovarian Germ Cell Tumor
- Recurrent Pancreatic Carcinoma
- Recurrent Rectal Carcinoma
- Recurrent Renal Cell Carcinoma
- Stage III Pancreatic Cancer
- Stage III Renal Cell Cancer
- Stage IIIA Colon Cancer
- Stage IIIA Non-Small Cell Lung Cancer
- Stage IIIA Ovarian Cancer
- Stage IIIA Ovarian Germ Cell Tumor
- Stage IIIA Rectal Cancer
- Stage IIIA Skin Melanoma
- Stage IIIB Breast Cancer
- Stage IIIB Colon Cancer
- Stage IIIB Non-Small Cell Lung Cancer
- Stage IIIB Ovarian Cancer
- Stage IIIB Ovarian Germ Cell Tumor
- Stage IIIB Rectal Cancer
- Stage IIIB Skin Melanoma
- Stage IIIC Breast Cancer
- Stage IIIC Colon Cancer
- Stage IIIC Ovarian Cancer
- Stage IIIC Ovarian Germ Cell Tumor
- Stage IIIC Rectal Cancer
- Stage IIIC Skin Melanoma
- Stage IV Breast Cancer
- Stage IV Non-Small Cell Lung Cancer
- Stage IV Ovarian Cancer
- Stage IV Ovarian Germ Cell Tumor
- Stage IV Pancreatic Cancer
- Stage IV Renal Cell Cancer
- Stage IV Skin Melanoma
- Stage IVA Colon Cancer
- Stage IVA Rectal Cancer
- Stage IVB Colon Cancer
- Stage IVB Rectal Cancer
Interventions
- DRUG
-
Gamma-Secretase Inhibitor RO4929097
Given PO
- DRUG
-
Cediranib Maleate
Given PO
- OTHER
-
Pharmacological Study
Correlative studies
- OTHER
-
Laboratory Biomarker Analysis
Correlative studies
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
Sebastien Hotte · University Health Network-Princess Margaret Hospital
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2010-05-31
- Primary Completion
- 2014-09-30
- Completion
- 2014-09-30
Countries
- Canada
Study Locations
More Related Trials
-
An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies
NCT02712905 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery
NCT00608361 ·Status: COMPLETED ·Phase: PHASE1
-
Lenvatinib and Capecitabine in Patients With Advanced Malignancies
NCT02915172 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
NCT06022029 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849
NCT05761223 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Open Label Phase I/II Clinical Trial to Evaluate CPI-613 in Patients With Advanced Malignancies
NCT00741403 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors
NCT02650713 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
NCT00811993 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
NCT05581004 ·Status: RECRUITING ·Phase: PHASE1
-
Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients
NCT01832857 ·Status: TERMINATED ·Phase: PHASE2
-
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
NCT00004241 ·Status: COMPLETED ·Phase: PHASE1
-
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN
NCT04317105 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
First-in-Human Study of MS201408-0005A as Single Agent and in Combinations
NCT03306420 ·Status: TERMINATED ·Phase: PHASE1
-
AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
NCT00324597 ·Status: UNKNOWN ·Phase: PHASE1
-
Dose Escalation, Combination Chemotherapy Safety Study of Birinapant (TL32711), in Subjects With Advanced or Metastatic Solid Tumors
NCT01188499 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors
NCT06573294 ·Status: TERMINATED ·Phase: PHASE1
-
A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma
NCT04434469 ·Status: COMPLETED ·Phase: PHASE1
-
Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors
NCT00002902 ·Status: COMPLETED ·Phase: PHASE1
-
PR-104 in Treating Patients With Advanced Solid Tumors
NCT00349167 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Evaluate IMP9064 as a Monotherapy or in Combination in Patients With Advanced Solid Tumors
NCT05269316 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
NCT02608268 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT04644068 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors
NCT00701298 ·Status: TERMINATED ·Phase: PHASE1
-
A Trial to Find the Safe Dose for BI 905681 in Patients With Incurable Tumours or Tumours That Have Spread
NCT04147247 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens
NCT01009190 ·Status: COMPLETED ·Phase: PHASE1